AIHTA - Publications - Search - Entrectinib (Rozlytrek®) for the treatment of patients whose solid tumours have a NTRK gene fusion, or patients with ROS1-positive advanced NSCLC

Grössmann, N. (2020): Entrectinib (Rozlytrek®) for the treatment of patients whose solid tumours have a NTRK gene fusion, or patients with ROS1-positive advanced NSCLC. Oncology Fact Sheet Nr. 13.

[thumbnail of Oncology Fact Sheet Nr.13.pdf]
Preview
PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
67kB

Item Type:Oncology Fact Sheets
Subjects:QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
QZ Pathology > QZ 200-380 Neoplasms.Cysts
WB Practice of medicine > WB 300-962 Therapeutics
WF Respiratory system
Language:English
Series Name:Oncology Fact Sheet Nr. 13
Deposited on:02 Jul 2020 09:49
Last Modified:15 Jul 2020 18:02

Repository Staff Only: item control page